GlassScriptPhysician profile
Oscar Rodriguez
NPI 1619983780
$2,038.08
in general payments reported to CMS, 2019-2025
22 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $362 · 2021: $280 · 2022: $283 · 2023: $229 · 2024: $186 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $409.30 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $278.50 | 2019-2023 | |
| Abbvie INC. | $216.83 | 2020-2025 | Linzess, Viberzi, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.09 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Allergan, INC. | $169.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $136.22 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $117.92 | 2019-2024 | Rybelsus |
| Janssen Pharmaceuticals, INC | $114.68 | 2019-2021 | |
| Mylan Specialty L.P. | $105.63 | 2021-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $46.40 | 2021-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $30.64 | 2020-2021 | |
| Lilly USA, LLC | $29.44 | 2023 | Mounjaro |
| Abbott Laboratories | $26.67 | 2021-2022 | |
| Glaxosmithkline, LLC. | $21.24 | 2025 | Trelegy Ellipta |
| Ferring Pharmaceuticals INC. | $19.33 | 2023 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.31 | 2023 | |
| Vanda Pharmaceuticals INC. | $17.20 | 2025 | Fanapt |
| Kyowa Kirin, INC. | $15.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.79 | 2022 | |
| Recordati_rare_diseases_inc. | $15.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Eisai INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.